PBYI PUMA BIOTECHNOLOGY, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%
Margins
Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%
Returns
ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x
Cash quality & payout
Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $55.06M | $56.50M | $44.81M | $75.45M | $54.48M | $52.44M | $46.01M | $59.08M |
| Cost of revenue | $15.20M | $12.47M | $10.42M | $23.13M | $12.17M | $12.30M | $10.56M | $13.92M |
| Gross profit | $39.86M | $44.03M | $34.39M | $52.33M | $42.30M | $40.13M | $35.45M | $45.16M |
| R&D expense | $18.28M | $18.89M | $19.80M | $16.84M | $15.91M | $15.45M | $13.86M | $15.17M |
| SG&A expense | $16.30M | $17.55M | $18.42M | $18.38M | $16.82M | $18.05M | $17.60M | $16.62M |
| Operating income | $5.27M | $7.58M | -$3.83M | $17.11M | $9.57M | $6.64M | $3.98M | $13.37M |
| Interest expense | $0 | $180,000 | $731,000 | $1.12M | $1.49M | $1.84M | $2.18M | $2.62M |
| Pretax income | $6.17M | $8.24M | -$3.43M | $17.11M | $9.24M | $6.17M | $3.27M | $12.24M |
| Income tax | — | — | — | — | — | — | — | -$7.07M |
| Net income | $5.96M | $8.19M | -$3.75M | $13.44M | $8.84M | $5.86M | $2.97M | $19.30M |
| EBITDA | $7.73M | $10.10M | -$1.24M | $19.76M | $9.67M | $6.74M | $6.78M | $16.21M |
| EPS (basic) | 0.12 | 0.16 | -0.07 | — | 0.18 | 0.12 | 0.06 | — |
| EPS (diluted) | 0.11 | 0.16 | -0.07 | — | 0.17 | 0.12 | 0.06 | — |
| Weighted avg. shares (diluted) | 53.12M | 52.60M | 50.85M | — | 50.93M | 50.14M | 49.91M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.55M | $36.54M | $36.19M | $29.64M | $53.52M | $54.66M | $63.03M | $69.22M |
| Short-term investments | $67.03M | $57.37M | $65.35M | $67.89M | $40.86M | $41.36M | $30.14M | $31.75M |
| Receivables | $32.83M | $34.06M | $26.33M | $53.65M | $33.56M | $25.91M | $25.17M | $32.01M |
| Inventory | $11.49M | $13.32M | $8.69M | $5.51M | $9.48M | $8.59M | $8.75M | $8.72M |
| Current assets | $157.63M | $145.07M | $142.26M | $162.69M | $143.58M | $136.58M | $132.51M | $147.66M |
| PP&E, net | $84,000 | $103,000 | $124,000 | $187,000 | $305,000 | $388,000 | $474,000 | $515,000 |
| Intangibles | — | — | — | $41.39M | — | — | — | $51.13M |
| Total assets | $202.77M | $192.74M | $192.70M | $216.30M | $202.86M | $194.92M | $196.18M | $213.33M |
| Current liabilities | $51.97M | $49.83M | $59.74M | $81.25M | $82.73M | $79.10M | $86.66M | $96.11M |
| Short-term debt | $0 | $0 | $11.28M | $22.52M | $33.72M | $34.00M | $45.33M | $45.33M |
| Long-term debt | — | $0 | $0 | $0 | $0 | $10.87M | $10.65M | $21.72M |
| Total debt | — | $0 | $11.28M | $22.52M | $33.72M | $44.87M | $55.98M | $67.05M |
| Total liabilities | $56.15M | $54.19M | $64.28M | $85.96M | $87.59M | $90.20M | $99.07M | $121.21M |
| Shareholders' equity | $146.61M | $138.54M | $128.42M | $130.34M | $115.27M | $104.72M | $97.11M | $92.12M |
| Net debt | — | -$36.54M | -$24.91M | -$7.11M | -$19.81M | -$9.80M | -$7.05M | -$2.17M |
| Shares outstanding | 51.69M | 51.10M | 50.88M | 50.41M | 50.38M | 49.89M | 49.62M | 49.11M |
| Cash flow statement | ||||||||
| Operating cash flow | $14.58M | $1.62M | $15.42M | $14.42M | $9.69M | $14.08M | $3.61M | $15.61M |
| Capital expenditure | $0 | $0 | $0 | -$36,000 | $26,000 | $20,000 | $61,000 | $16,000 |
| Free cash flow | $14.58M | $1.62M | $15.42M | $14.46M | $9.66M | $14.06M | $3.55M | $15.59M |
| Investing cash flow | -$9.71M | $7.97M | $2.47M | -$26.98M | $506,000 | -$11.25M | $1.53M | -$2.32M |
| Financing cash flow | $146,000 | -$11.34M | -$11.33M | -$11.33M | -$11.33M | -$11.20M | -$11.33M | -$11.33M |
| Depreciation & amortization | $2.45M | $2.52M | $2.58M | $2.66M | $100,000 | $100,000 | $2.80M | $2.84M |
| Stock-based compensation | $2.02M | $1.95M | $1.90M | $1.62M | $1.67M | $1.63M | $2.03M | $1.75M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.